GB2599340A — Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities

USPTO Abstract

A Cannabidiol (CBD) preparation for use in the treatment of seizures associated with MECP2 duplication syndrome. The seizures can be tonic and myoclonic seizures. The CBD preparation can comprise greater than 95% (w/w) CBD and not more than 0.15% (w/w) tetrahydrocannabinol (THC). The CBD preparation can comprise greater than or equal to 98% (w/w) CBD and less than or equal to 2% (w/w) other cannabinoids. The other cannabinoids can comprise tetrahydrocannabinol (THC), cannabidiol-C1 (CBD-C1), cannabidivarin (CBDV), and cannabidiol-C4 (CBD-C4) and wherein the THC is present as a mixture of trans-THC and cis-THC. The CBD preparation can be used with one or more concomitant anti-epileptic drugs (AED). The AED can be valproic acid, clobazam, lacosamide, and lamotrigine. The CBD can be isolated from cannabis plant material. The CBD preparation can be a synthetic preparation. The CBD preparation can be administered at a dose greater than 5 mg/kg/day or at a dose of either 20 mg/kg/day, 25 mg/kg/day, or 50 mg/kg/day. A further aspect of the invention is a method of treating seizures associated with MECP2 duplication syndrome by administering a CBD preparation.